Antisoma has said it will halt trials of its non-small cell lung cancer drug candidate ASA404 following poor interim data analysis from Phase III trials.

The interim analysis indicated that the continuation of the trial would be futile as the drug candidate showed little or no prospect of survival benefit.

The study coded Attract-1 has not revealed new or unexpected serious adverse effects.